HCA
TRDA icon

Harbor Capital Advisors’s Entrada Therapeutics TRDA Stock Holding History

Harbor Capital Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Buy
33,351
+15,176
+83% +$146K 0.02% 606
2026
Q1 		$229K Buy
+18,175
New +$208K 0.02% 582
2025
Q3 		– Sell
-15,277
Closed -$103K – 1488
2025
Q2 		$103K Buy
15,277
+1,874
+14% +$15.1K ﹤0.01% 647
2025
Q1 		$121K Buy
+13,403
New +$167K 0.01% 645
2024
Q2 		– Sell
-14,543
Closed -$206K – 771
2024
Q1 		$206K Buy
+14,543
New +$206K 0.03% 593

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Harbor Capital Advisors's TRDA Position: Q2 2026 in Review

Harbor Capital Advisors increased its Entrada Therapeutics (TRDA) stake by 83% in Q2 2026, buying an estimated $146K and bringing the position to 33,351 shares worth $245K. The position accounts for 0.02% of the portfolio, ranked #606.

Harbor Capital Advisors first reported a position in TRDA in Q1 2024 and has held it in 5 quarters since. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Harbor Capital Advisors held 33,351 shares of Entrada Therapeutics worth $245K as of Q2 2026.
  • Harbor Capital Advisors bought 15,176 Entrada Therapeutics shares in Q2 2026, an estimated $146K.
  • Entrada Therapeutics made up 0.02% of Harbor Capital Advisors's portfolio in Q2 2026, its #606 holding.
  • Harbor Capital Advisors first reported a position in Entrada Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.